The FDA has broadened the indication for dostarlimab-gxly to include the treatment of endometrial cancer in combination with chemotherapy

August 2024: The Food and Drug Administration has granted approval for dostarlimab-gxly (Jemperli, GSK) in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for the treatment of adult patients..

Abemaciclib, aromatase inhibitor, Eli Lilly and Company, endocrine therapy, Tamoxifen, Verzenio

Abemaciclib with endocrine therapy is approved by FDA in HER 2 positive breast cancer

March 2023: Abemaciclib (Verzenio, Eli Lilly and Company) and endocrine therapy (tamoxifen or an aromatase inhibitor) have been approved by the Food and Drug Administration (FDA) for the adjuvant treatment of adult patients with ..

CAR T Cell therapy trials, Glioblastoma, glioblastoma trials, gliomas

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

March 2023: Study Type : Interventional (Clinical Trial)Estimated Enrollment : 30 participantsAllocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: a "3+3" design is used to determine Maximum..

American Society of Hematology, Carteyva, China, JW Therapeutics, relmacabtagene autoleucel

JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting

SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products. At the 64th American Society ..

dMMR, Dostarlimab-gxly, GlaxoSmithKline, Jemperli

Dostarlimab-gxly is approved by FDA for dMMR endometrial cancer

Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed during or after a prior ..

Daiichi Sankyo, DESTINY-Breast04, Enhertu, fam-trastuzumab deruxtecan-nxki

Fam-trastuzumab deruxtecan-nxki is approved by FDA for HER2-low breast cancer

August 2022: For adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH) breast cancer who have received prior chemotherapy in the metastatic setting or experienced a disease recurrence during or within six..

AstraZeneca Pharmaceuticals, BRCA, gBRCAm, Lynparza, olaparib, OlympiA

Olaparib is approved for adjuvant treatment of high-risk early breast cancer

March 2022: The Food and Drug Administration has approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) h..

Atezolizumab, Bevacizumab, nivolumab, Regorafenib, Stivarga, Tecentriq

Drugs approved for treatment of liver cancer

Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-S-M..

FDA, KRAS G12C, Lumakras, NSCLC, sotorasib

The FDA has approved the first targeted therapy for a lung cancer mutation that was previously thought to be drug-resistant

August 20, 2021: Recently in May, 2021 Lumakras (sotorasib) was approved by the US Food and Drug Administration as the first treatment for adult patients with non-small cell lung cancer who have undergone at least one prior system..

KEYTRUDA, Merck, NCT02362594, Pembrolizumab, RECIST, USFDA

Pembrolizumab is approved by FDA for adjuvant treatment of melanoma

On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..